title: Ocriplasmin for vitreoretinal diseases.
abstract: Fibronectin and laminin are clinically relevant plasmin receptors in the eye. Located at the vitreoretinal interface, they are cleaved by ocriplasmin (Microplasmin, ThromboGenics, Iselin, NJ), a novel ophthalmic medication. A series of clinical trials to study ocriplasmin for the treatment of vitreoretinal diseases such as vitreomacular traction, macular hole, and exudative age-related macular degeneration are underway. The results are promising and may impact patient care.
authors.affiliation: Retina Division, Jules Stein Eye Institute, University of California, Los Angeles, CA 90095, USA. itsui@jsei.ucla.edu
authors.forename: Irena
authors.initials: I
authors.lastname: Tsui
authors.forename: Carolyn K
authors.initials: CK
authors.lastname: Pan
authors.forename: Ehsan
authors.initials: E
authors.lastname: Rahimy
authors.forename: Steven D
authors.initials: SD
authors.lastname: Schwartz
mesh_terms: D000818:Animals; D017277:Drug Approval; D005341:Fibrinolysin / Q000008:administration & dosage / Q000378:metabolism / Q000494:pharmacology* / Q000627:therapeutic use*; D006801:Humans; D010446:Peptide Fragments / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D012164:Retinal Diseases / Q000188:drug therapy* / Q000473:pathology; D014822:Vitreous Body / Q000187:drug effects* / Q000473:pathology* / Q000601:surgery
chemical_list: D010446:Peptide Fragments; C054561:microplasmin; D005341:Fibrinolysin